B. Riley maintains its buy rating on Compass Pathways as COMP360 advances toward a possible US launch and psilocybin therapy infrastructure begins to take shape

Compass Pathways remains positioned as a commercial-stage psychedelic medicine company in investors' eyes as B. Riley reiterates its positive rating and frames the business around launch readiness for COMP360. The focus centers on how a psilocybin therapy model could move from late-stage development into practical delivery if regulatory milestones are met. COMP360 is Compass Pathways' synthetic psilocybin candidate, aimed primarily at treatment-resistant depression. The launch setup typically includes clinic network preparation, therapist training, reimbursement planning, and operational systems needed for a supervised psychedelic treatment model rather than a conventional take-home drug. Market interest reflects more than trial data alone. Commercial viability depends on whether psilocybin-assisted therapy can scale within real healthcare settings, navigate payer adoption, and convert regulatory progress into sustainable revenue.